Histrelin API is a pharmaceutical-grade Gonadotropin-Releasing Hormone (GnRH) agonist used in the treatment of advanced prostate cancer, central precocious puberty (CPP), and other hormone-dependent disorders. It initially stimulates and subsequently suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to reduced testosterone or estrogen production.
Histrelin is commonly administered through long-acting subcutaneous implants, providing continuous hormone suppression over an extended period. It is widely used in endocrinology, oncology, and pediatric medicine due to its sustained therapeutic efficacy.
Manufactured under WHO-GMP-certified facilities, our Histrelin API offers exceptional purity, peptide stability, and batch-to-batch consistency. Every batch is supplied with complete regulatory documentation, including Certificate of Analysis (CoA), Material Safety Data Sheet (MSDS), and Technical Data Sheet (TDS).
Histrelin API is used for the treatment of advanced prostate cancer, central precocious puberty (CPP), and other hormone-dependent conditions.
Histrelin acts as a GnRH agonist, initially stimulating and then suppressing LH and FSH secretion, leading to reduced testosterone or estrogen production.
Yes. We provide commercial bulk quantities with CoA, MSDS, and complete regulatory documentation.
Get Bulk Quote via WhatsApp